The role of gut bacteria on the maturation of the immune system was discovered by new research from the RIKEN Center for Integrative Medical Sciences in Japan. It provides evidence supporting the use of butyrate as therapy for inflammatory bowel diseases like Crohn's disease.
Published in the journal Nature today, the Japanese study shows that butyrate, a by-product of the digestion of dietary fiber by gut microbes, acts as an epigenetic switch that boosts the immune system by inducing the production of regulatory T cells in the gut.
Previous studies have shown that patients suffering from inflammatory bowel disease lack butyrate-producing bacteria and have lower levels of butyrate in their gut. However, butyrate's anti-inflammatory properties were attributed to its role as main energy source for the cells lining the colon. This study is the first to provide a molecular basis for the role of butyrate on the production of regulatory T lymphocytes
Their research demonstrates that butyric acid, a short-chain fatty acid produced by commensal bacteria acts on naïve T cells to promote their differentiation into Treg cells. It achieves this through epigenetic changes that regulate the expression of the genes responsible for differentiation of naïve T cells into Treg cells.
The study shows that mice suffering from colitis see their levels of Treg cells increase and their symptoms improve after administration of butyrate as part of their diet.
"Regulatory T cells are important for the containment of excessive inflammatory responses as well as autoimmune disorders. Therefore these findings could be applicable for the prevention and treatment of inflammatory bowel disease (IBD), allergy and autoimmune disease," said Dr Hiroshi Ohno.
"Butyrate is natural and safe as a therapy and in addition to that it is cheap, which could reduce costs for both patients and society," Dr Ohno added.